Mark W. Hahn, Chief Financial Officer at Verona Pharma plc (VRNA), sold 1,705,736 shares at $5.00 ($8.5M) on 2024-12-04, disclosed to the SEC on 2024-12-06.
Scheduled sale ($8.5M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $5.00 | 58,184 | $291K | 3.4% |
| 2 | $5.01 | 640,048 | $3.2M | 37.5% |
| 3 | $5.01 | 640,048 | $3.2M | 37.5% |
| 4 | $5.01 | 183,728 | $920K | 10.8% |
| 5 | $5.01 | 183,728 | $920K | 10.8% |
| Total | $5.01 avg | 1,705,736 |
| $8.5M |
| 100% |
| Filing → |
| VRNA | SELL | 2025-05-29 | $7.5M | — | Filing → |
| VRNA | SELL | 2025-05-05 | $7.0M | — | Filing → |
| VRNA | SELL | 2025-05-01 | $1.6M | — | Filing → |